Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis

Part of paid clinical trials in Portland, Oregon.

Sponsor: Eric B. Suhler
Study ID: NCT01603355
Phase: PHASE1/PHASE2
Status: Terminated

Conditions

Juvenile Idiopathic Arthritis Associated Uveitis

Eligibility Criteria

Sex: ALL
Age: 2 Years - 17 Years
Healthy Volunteers: Not accepted

Interventions

Tocilizumab — DRUG
Intravenous tocilizumab: Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks

Study Details

The investigators are doing this research study to see if tocilizumab (Actemra) is safe and effective when used for severe or refractory non-infectious uveitis. Uveitis is an inflammation of the eye that is caused by the body's immune system reacting against the eye tissues.

Key Dates

Start date: Nov 30, 2013
Status verified: Jan 2019
Primary completion: Feb 29, 2016
Completion: Feb 29, 2016

Study Design

Enrollment: 3 participants (actual)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: Tocilizumab

Primary Outcome Measure

Number of Participants With Control of Ocular Inflammation [ Time Frame: 16 Weeks ]

Locations (1)

Facility	City	State	ZIP	Site coordinators
Oregon Health & Science University	Portland	Oregon	97239	-

Find similar trials in Portland, OR

By research site

Oregon Health & Science University· Portland, OR